Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 50 years, inclusive, who are long-term residents of Gabon.~* Good general health as determined by means of the screening procedure.~* Assumed availability for the duration of the trial (12 months).~* Willingness to participate in the study as evidenced by signing the informed consent document.~* Negative for hookworm during screening, or if found to be infected with hookworm, has completed a course of three doses of albendazole.~Exclusion Criteria:~* Pregnancy as determined by a positive urine hCG (if female).~* Participant unwilling to use reliable contraception up until one month following the third immunization (if female and not surgically sterile, abstinent or at least 2 years post-menopausal).~* Currently lactating and breast-feeding (if female).~* Inability to correctly answer all questions on the informed consent comprehension questionnaire.~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.~* Known or suspected immunodeficiency.~* Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 1.25-times the upper reference limit).~* Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing).~* Laboratory evidence of hematologic disease (absolute leukocyte count \<3500/mm3; absolute leukocyte count \>11.0 x 103/mm3; hemoglobin \<10.000 g/dl \[females\] or \<12.0 g/dl \[males\]; or, platelet count \<140,000/mm3).~* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.~* Participation in another investigational vaccine or drug trial within 30 days of starting this study or for the duration of the study.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of a severe allergic reaction or anaphylaxis.~* Severe asthma as defined by the need for daily use of inhalers or emergency room/clinic visit or hospitalization within 6 months of the volunteer's planned first vaccination in the study.~* Positive for HCV~* Positive ELISA for HBsAg.~* Positive for HIV infection~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study or expect to use for the duration of the study.~* Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.~* History of a surgical splenectomy.~* Receipt of blood products within the 6 months prior to entry into the study.~* Previous receipt of a primary series of any hepatitis B vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 30 µg Na-GST-1 + 30 µg Na-APR-1 (M74) (Type: EXPERIMENTAL): 30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
- Hepatitis B vaccine (Type: ACTIVE_COMPARATOR): Hepatitis B vaccine co-administered with saline
- 100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74) (Type: EXPERIMENTAL): 100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF

Based on this trial design, predict the completion outcome and termination type (if applicable).